Medpace Holdings, Inc. (NASDAQ:MEDP) Receives Average Rating of “Hold” from Brokerages

Medpace Holdings, Inc. (NASDAQ:MEDP) has been assigned a consensus rating of “Hold” from the eleven research firms that are currently covering the firm, MarketBeat Ratings reports. Six analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $380.56.

MEDP has been the subject of a number of analyst reports. StockNews.com lowered shares of Medpace from a “buy” rating to a “hold” rating in a research report on Friday, September 27th. Redburn Atlantic began coverage on shares of Medpace in a research report on Monday, October 14th. They set a “buy” rating and a $404.00 price target for the company. William Blair reaffirmed an “outperform” rating on shares of Medpace in a research report on Tuesday, October 22nd. UBS Group lowered shares of Medpace from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $420.00 to $350.00 in a research report on Friday, September 27th. Finally, Jefferies Financial Group lowered shares of Medpace from a “buy” rating to a “hold” rating and dropped their price target for the stock from $415.00 to $345.00 in a research report on Wednesday, September 25th.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $337.35 on Friday. Medpace has a 12-month low of $284.32 and a 12-month high of $459.77. The company has a market capitalization of $10.48 billion, a PE ratio of 29.54, a price-to-earnings-growth ratio of 1.80 and a beta of 1.36. The firm’s 50-day moving average is $340.52 and its two-hundred day moving average is $357.30.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, October 21st. The company reported $3.01 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.24. The business had revenue of $533.32 million during the quarter, compared to analyst estimates of $540.99 million. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The company’s revenue was up 8.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.22 earnings per share. On average, analysts forecast that Medpace will post 11.93 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Lifestyle Asset Management Inc. grew its holdings in Medpace by 6.0% during the 4th quarter. Lifestyle Asset Management Inc. now owns 3,917 shares of the company’s stock worth $1,301,000 after acquiring an additional 220 shares in the last quarter. Janney Montgomery Scott LLC raised its position in shares of Medpace by 562.3% during the 4th quarter. Janney Montgomery Scott LLC now owns 54,761 shares of the company’s stock worth $18,193,000 after buying an additional 46,493 shares in the last quarter. SG Americas Securities LLC raised its position in shares of Medpace by 967.4% during the 4th quarter. SG Americas Securities LLC now owns 24,593 shares of the company’s stock worth $8,171,000 after buying an additional 22,289 shares in the last quarter. Barlow Wealth Partners Inc. bought a new stake in shares of Medpace during the 4th quarter worth about $1,383,000. Finally, Nisa Investment Advisors LLC grew its stake in shares of Medpace by 6.9% in the 4th quarter. Nisa Investment Advisors LLC now owns 701 shares of the company’s stock worth $233,000 after purchasing an additional 45 shares during the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.